Table 3.

Baseline characteristics and clinical outcomes and clinical outcomes of patients taking only oral PPIs at baseline that were continued for >2 days compared with patients not prescribed PPIs during hospitalisation or at discharge.

	PPI at baseline	Non-PPI at baseline	P value
Baseline Clinical Characteristics
Number	317	295
Mean age (yrs)	53.71 (10.9)	53.5 (10.6)	0.81
Male	229 (72.2%)	208 (70.5%)	0.73
Female	88 (27.8%)	87 (29.5%)	0.73
Alcohol	293 (92.4%)	257 (87.1%)	0.05
Alcoholic Hepatitis	86 (27.3%)	70 (23.7%)	0.37
Albumin treatment	158 (49.8%)	150 (50.8%)	0.28
NSBB use	83 (26.2%)	37 (12.5%)	2.36489E-05∗
Suspected Variceal Bleed	45 (14.3%)	14 (4.75%)	8.95954E-05∗
Ascites	203 (64.4%)	208 (70.5%)	0.08
Use of antibiotics	162 (51.1%)	137 (46.4%)	0.30
MELD Score - median (95% CI)	18.9 (17.7–20.1)	19.58 (18.6–20.6)	0.08
Serum Albumin g/L - median (95% CI)	24 (23–24)	24 (23–24)	0.89
Creatinine mmol/L -median (95% CI)	68 (63–72)	66 (63–69)	0.19
WCC x109/L - median (95% CI)	7.3 (6.7–7.7)	8.1 (7.5–8.8)	0.0038∗
CRP mg/L - median (95% CI)	26 (22–30)	23 (21–29)	0.79
Bilirubin mg/L median (95% CI)	84 (70–98)	109 (94–127)	0.0027∗
Primary Clinical Outcomes
Diagnosis of infection at randomisation	85 (26.8%)	80 (27.1%)	0.89
Incidence of new infection (days 3–15)	54 (17%)	54 (18.3%)	0.68
New infection reported as SBP	4 (1.3%)	5 (1.7%)	N/A
HE at randomisation (all grades)	61 (19.4%)	46 (15.6%)	0.26
Incidence of new grade III/IV HE (days 3–15)	21 (6.6%)	11 (3.7%)	0.11
Incidence of new grade I/II HE (days 3–15)	25 (7.9%)	22 (7.5%)	0.84
Secondary Clinical Outcomes
Incidence of renal dysfunction (days 3–15)	39 (12.3%)	32 (10.9%)	0.57
Incidence of death during hospitalisation (days 3–15)	19 (6%)	24 (8.5%)	0.3
28-day mortality	43 (13.6%)	40 (13.6%)	0.99
90-day mortality	72 (22.7%)	67 (22.7%)	0.99
180-day mortality	97 (30.6%)	95 (32.2%)	0.67

∗P values < 0.05.